AU2015349610B2 - Method of treating or preventing stroke - Google Patents
Method of treating or preventing stroke Download PDFInfo
- Publication number
- AU2015349610B2 AU2015349610B2 AU2015349610A AU2015349610A AU2015349610B2 AU 2015349610 B2 AU2015349610 B2 AU 2015349610B2 AU 2015349610 A AU2015349610 A AU 2015349610A AU 2015349610 A AU2015349610 A AU 2015349610A AU 2015349610 B2 AU2015349610 B2 AU 2015349610B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- antibody
- stroke
- vegf
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21068—Tissue plasminogen activator (3.4.21.68), i.e. tPA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24029—Aureolysin (3.4.24.29)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Plant Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2014904606 | 2014-11-17 | ||
AU2014904606A AU2014904606A0 (en) | 2014-11-17 | Method of treating or preventing stroke | |
PCT/AU2015/050720 WO2016077878A1 (fr) | 2014-11-17 | 2015-11-17 | Méthode de traitement ou de prévention d'un accident vasculaire cérébral |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2015349610A1 AU2015349610A1 (en) | 2017-05-25 |
AU2015349610B2 true AU2015349610B2 (en) | 2021-08-26 |
Family
ID=56012959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2015349610A Active AU2015349610B2 (en) | 2014-11-17 | 2015-11-17 | Method of treating or preventing stroke |
Country Status (13)
Country | Link |
---|---|
US (2) | US10336821B2 (fr) |
EP (1) | EP3220952B1 (fr) |
JP (1) | JP6863892B2 (fr) |
KR (1) | KR102560025B1 (fr) |
CN (1) | CN107106681B (fr) |
AU (1) | AU2015349610B2 (fr) |
BR (1) | BR112017010336A2 (fr) |
CA (1) | CA2967070C (fr) |
DK (1) | DK3220952T3 (fr) |
ES (1) | ES2881303T3 (fr) |
PL (1) | PL3220952T3 (fr) |
RU (1) | RU2744909C2 (fr) |
WO (1) | WO2016077878A1 (fr) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10617756B2 (en) * | 2017-01-05 | 2020-04-14 | Shimojani, LLC | Drug regimen for treatment of cerebral ischemia |
EP3681497A4 (fr) * | 2017-09-13 | 2021-06-02 | The Regents of The University of Michigan | Inhibition de la protéine kinase c pour prolonger le traitement de l'activateur tissulaire du plasminogène pour une maladie ischémique |
WO2019104385A1 (fr) * | 2017-11-29 | 2019-06-06 | Csl Limited | Procédé de traitement ou de prévention d'une lésion liée à l'ischémie-reperfusion |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009126698A2 (fr) * | 2008-04-09 | 2009-10-15 | Ludwig Institute For Cancer Research | Régulation de transporteurs d'acides gras |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030232439A1 (en) | 2002-06-17 | 2003-12-18 | Isis Pharmaceuticals Inc. | Antisense modulation of VEGF-B expression |
DK1781321T3 (da) * | 2004-08-02 | 2014-04-14 | Zenyth Operations Pty Ltd | Fremgangsmåde til behandling af cancer, der omfatter en vegf-b-antagonist |
CN101370525B (zh) * | 2005-08-19 | 2013-09-18 | Abbvie公司 | 双重可变结构域免疫球蛋白及其用途 |
US8114399B2 (en) | 2006-05-17 | 2012-02-14 | Ludwig Institute For Cancer Research | Targeting VEGF-B regulation of fatty acid transporters to modulate human diseases |
US20110318365A1 (en) | 2007-09-15 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Methods for treatment of degenerative disease associated with apoptosis |
JP5823671B2 (ja) * | 2009-07-27 | 2015-11-25 | 国立大学法人 新潟大学 | 免疫製剤を含む脳梗塞治療用医薬品組成物 |
RU2718054C2 (ru) | 2013-11-28 | 2020-03-30 | СиЭсЭл ЛИМИТЕД | Способ лечения нефропатии |
KR20160096194A (ko) | 2013-12-18 | 2016-08-12 | 씨에스엘 리미티드 | 상처 치료 방법 |
-
2015
- 2015-11-17 DK DK15861231.7T patent/DK3220952T3/da active
- 2015-11-17 EP EP15861231.7A patent/EP3220952B1/fr active Active
- 2015-11-17 WO PCT/AU2015/050720 patent/WO2016077878A1/fr active Application Filing
- 2015-11-17 CA CA2967070A patent/CA2967070C/fr active Active
- 2015-11-17 BR BR112017010336A patent/BR112017010336A2/pt active Search and Examination
- 2015-11-17 AU AU2015349610A patent/AU2015349610B2/en active Active
- 2015-11-17 US US15/527,066 patent/US10336821B2/en active Active
- 2015-11-17 KR KR1020177016154A patent/KR102560025B1/ko active IP Right Grant
- 2015-11-17 JP JP2017526138A patent/JP6863892B2/ja active Active
- 2015-11-17 CN CN201580073640.8A patent/CN107106681B/zh active Active
- 2015-11-17 PL PL15861231T patent/PL3220952T3/pl unknown
- 2015-11-17 ES ES15861231T patent/ES2881303T3/es active Active
- 2015-11-17 RU RU2017120031A patent/RU2744909C2/ru active
-
2019
- 2019-05-14 US US16/411,321 patent/US10961304B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009126698A2 (fr) * | 2008-04-09 | 2009-10-15 | Ludwig Institute For Cancer Research | Régulation de transporteurs d'acides gras |
Non-Patent Citations (3)
Title |
---|
CAROLINA E. HAGBERG ET AL, "Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes", NATURE, (2012-01-01), vol. 490, no. 7420, doi:10.1038/nature11464, ISSN 0028-0836, pages 426 - 430 * |
NICHOLAS VAN BRUGGEN ET AL, "VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain", THE JOURNAL OF CLINICAL INVESTIGATION, (1999-12), vol. 104, no. 11, pages 1613 - 1620 * |
ZHENG GANG ZHANG, LI ZHANG, QUAN JIANG, RUILAN ZHANG, KENNETH DAVIES, CECYLIA POWERS, NICHOLAS VAN BRUGGEN, MICHAEL CHOPP: "VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain", THE JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, vol. 106, no. 7, 1 October 2000 (2000-10-01), GB, pages 829 - 838, XP055225450, ISSN: 0021-9738, DOI: 10.1172/JCI9369 * |
Also Published As
Publication number | Publication date |
---|---|
AU2015349610A1 (en) | 2017-05-25 |
RU2744909C2 (ru) | 2021-03-17 |
US20190315849A1 (en) | 2019-10-17 |
CA2967070A1 (fr) | 2016-05-26 |
CN107106681B (zh) | 2021-11-09 |
WO2016077878A1 (fr) | 2016-05-26 |
EP3220952A1 (fr) | 2017-09-27 |
DK3220952T3 (da) | 2021-07-19 |
KR102560025B1 (ko) | 2023-07-26 |
KR20170082631A (ko) | 2017-07-14 |
BR112017010336A2 (pt) | 2018-05-15 |
JP2017535551A (ja) | 2017-11-30 |
PL3220952T3 (pl) | 2022-01-31 |
CN107106681A (zh) | 2017-08-29 |
JP6863892B2 (ja) | 2021-04-21 |
US10336821B2 (en) | 2019-07-02 |
EP3220952B1 (fr) | 2021-04-21 |
RU2017120031A3 (fr) | 2019-05-15 |
US20180237513A1 (en) | 2018-08-23 |
EP3220952A4 (fr) | 2018-03-28 |
US10961304B2 (en) | 2021-03-30 |
CA2967070C (fr) | 2024-03-12 |
ES2881303T3 (es) | 2021-11-29 |
RU2017120031A (ru) | 2018-12-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11773171B2 (en) | WNT surrogate molecules and uses thereof | |
KR101999872B1 (ko) | 혈뇌 장벽 투과성의 조정에 있어서의 세마포린-4d 결합 분자의 용도 | |
US20240002488A1 (en) | Method of treating or preventing liver conditions | |
US10961304B2 (en) | Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B) | |
KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
JP2020029459A (ja) | 腎症を処置する方法 | |
EP2999715B1 (fr) | Nouvel anticorps utilisé dans les troubles neurologiques ou neurodégénératifs | |
EP3981787A1 (fr) | Anticorps anti-facteur de croissance de tissu conjonctif et son application | |
KR102466794B1 (ko) | 상처 치료 방법 | |
EP3901173A1 (fr) | Protéine bispécifique | |
KR20230007368A (ko) | 항-tmprss6 항체 및 이의 용도 | |
KR20240015200A (ko) | 뇌신경계 질환 치료하기 위한 병용투여용 항체 및 이를 포함하는 약학조성물 | |
CN114423788A (zh) | 抗nrp1a抗体及其用于治疗眼或眼部疾病的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |